REPORT DESCRIPTION
Fabry Disease Treatment Market– Overview
Fabry disease also called as Anderson-Fabry disease and alpha-galactosidase-A deficiency is an X-linked,
hereditary, lysosomal storage disease caused due to paucity of an enzyme α galactosidase A (an enzyme
required to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids). The mutated
gene leads the formation of lipids to harmful levels in various part of body such as the autonomic nervous
system, cardiovascular system, eyes, and kidneys. Some of the common symptoms of this multisystem
disorder include chronic pain, acroparesthesia, gastrointestinal disturbances, characteristic skin lesions
(angiokeratomata), progressive renal impairment, cardiomyopathy, and stroke.
The presence of robust medication pipeline indicated for treatment of Fabry disease is also expected to be a
major factor fueling growth of global Fabry disease treatment market over the forecast period. Table
mentioned below represents list of some novel therapies in pipeline for Fabry disease treatment.